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Abstract
Background: To describe the effects of intravitreal bevacizumab injection (IVB) and/or transpupillary thermotherapy
(TTT) in the treatment of small pigmented choroidal lesions with subfoveal fluid (SFF), and to investigate prognostic
value of the therapeutic response in future tumor growth.
Methods: Retrospective chart review of 19 patients, who were diagnosed with choroidal neovascularization (CNV)-
free small pigmented choroidal lesions and treated with IVB and/or TTT, was performed.
Results: Complete resolution of SFF was achieved in two eyes (2/14; 14.3%) after IVB, and in three eyes (3/4; 75%)
after TTT. Best corrected visual acuity was improved in two eyes (2/9; 22%) after IVB, and in three eyes (3/4; 75%)
after TTT. Among five patients who underwent TTT after IVB, four patients (4/5; 80%) demonstrated additional
advantage. All IVBs could not reduce tumor sizes. Rather, tumor growth was detected in seven out of 14 eyes (7/14;
50%) that underwent IVB. None of the patients who underwent TTT showed tumor growth. The lack of treatment
response to IVB was suggestive of malignancy, as most small pigmented lesions that had no response to IVB
showed tumor growth (86%, p = 0.010).
Conclusion: IVB was not effective in reducing tumor size and subfoveal fluid in small pigmented choroidal lesions.
Therapeutic response to IVB can be used as an indicator between melanoma and nevus in small pigmented choroidal
lesion.
Keywords: Bevacizumab, Subfoveal fluid, Small pigmented choroidal lesion, Transpupillary thermotherapy, Melanoma
Background
Small pigmented choroidal lesions may be choroidal nevus
or choroidal melanoma. It is very important to discrimin-
ate between benign choroidal nevus and small malignant
choroidal melanoma; however, their differential diagnosis
is not always easy. In addition, choroidal nevus is a subject
of interest due to its possible malignant transformation
into a melanoma [1], and thus, careful and continuous
observation may be required.
Shields et al. analyzed 2514 consecutive choroidal
nevus and identified the risk factors for transformation
to melanoma [1]. Intraocular tumors are not easy to per-
form a diagnostic biopsy on, due to low diagnostic
power and the risks of biopsy itself. Therefore, many on-
cologists are practically using these clinical risk factors
for differential diagnosis [1]. However, even if a small
pigmented choroidal lesion has known risk factors, it is
difficult to determine with certainty the destructive
treatments, such as enucleation or brachytherapy. How-
ever, observation alone can also be dangerous. Here, we
report the cases of small choroidal lesions with high risk
factors treated with intravitreal bevacizumab, which was
developed as an anti-cancer drug [2], and transpupillary
thermotherapy (TTT), which was a relatively simple
method to perform at the outpatient clinic.
Subretinal fluid (SRF) associated with choroidal nevus
is a risk factor for malignant transformation [1] and also
an indication for treatment, as it leads to visual symp-
toms [3, 4]. For patients with this condition, treatment is
required to prevent progressive loss of vision. There are
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various therapies to treat SRF, such as intravitreal
anti-vascular endothelial growth factor (VEGF) injection
[5–7], transpupillary thermotherapy (TTT) [8], and
photodynamic therapy (PDT) with verteporfin [9–11];
these methods have shown variable results.
Bevacizumab has been shown to be effective in reducing
neurosensory detachment by reducing the vascular perme-
ability in various ocular diseases, such as choroid-retinal
vascular diseases [12–16] and choroidal tumors [17–19]. If
choroidal neovascularization (CNV) is present, it can be
easily assumed that intravitreal anti-VEGF therapy may be
helpful. However, in this study, we have investigated the
effectiveness of anti-VEGF on subretinal fluid of small
pigmented choroidal lesion “without CNV.”
With the expectation of reducing tumor size and SRF,
we administered intravitreal bevacizumab injection (IVB)
as a treatment for symptomatic subfoveal fluid (SFF)
associated with small pigmented choroidal lesions. For
the same subjects and with the same purposes, we also
tried TTT as another treatment modality. TTT has been
suggested as one of the therapeutic strategies for SRF
associated with choroidal tumors [8, 17, 20].
In this study, we investigated the efficacy of IVB and
TTT in resolving SFF-associated small pigmented choroidal
lesions, and examined the relationship between treatment
response and future tumor growth. Moreover, we described
an unexpected effect of IVB on tumor growth.
Methods
We retrospectively reviewed medical records of all patients
who were diagnosed with small pigmented choroidal
lesions at the Yonsei University Eye and ENT Hospital,
between December 2005 and December 2016. Our study
was approved by the Institutional Review Board at Yonsei
University Medical Center (Reference No. 4–2017-0183)
before data review, and it also adhered to the tenets of the
Declaration of Helsinki.
Consecutive patients with small pigmented choroidal
lesions (posteriorly located, apical height < 3mm, and
largest basal diameter [LBD] < 12 mm, Stage 1 by Ameri-
can Joint Commission on Cancer [AJCC]) and associated
symptomatic SFF who were treated with IVB and/or
TTT were included in this study. Patients who did not
undergo follow-up examination after the initial diagnosis
were excluded. Eyes with pigmented choroidal lesions
with associated choroidal neovascularization were also
excluded from the study.
The following data were collected at the initial examin-
ation via fundus photography, ultrasonography, optical
coherence tomography (OCT; Stratus OCT, Carl Zeiss,
Dublin, CA or Spectralis HRA+OCT, Heidelberg Engin-
eering, Heidelberg, Germany), and fluorescein angiography
(FA; Heidelberg Retina Angiograph system, Heidelberg En-
gineering, Heidelberg, Germany): tumor size (LBD and
thickness), symptoms, surface features (orange pigmenta-
tion, drusen, and retinal pigment epithelium [RPE] alter-
ation), SRF, distance to foveola and optic disc margin, and
presence of choroidal neovascularization (CNV). Baseline
demographic data, including age and gender, were also
recorded. The observation of tumor growth or decrease
was defined as a change in size, of at least 0.3mm in any
dimension, which was determined by comparing fundus
photographs and B-scan ultrasonography images.
All patients were treated with IVB and/or TTT for
decreasing SFF. Using an aseptic technique, 1.25 mg of
bevacizumab was injected 3.0 or 3.5 mm posterior to the
limbus through the pars plana using a 30-gauge needle
in the operating room. TTT was performed under top-
ical anesthesia via dilated pupil. Patients were treated
with an infrared diode laser at 810 nm using a slit-lamp
biomicroscope delivery system. Each tumor was covered
entirely with confluent laser spots, with the power ran-
ging from 160 to 500mW and spot size between 1200
and 3000 μm to induce a slight color change with 1 min
of exposure at each spot. An area of 1 disc diameter
(DD) around the foveola and 1 DD around the disc
margin were spared during TTT in all cases. Before the
treatment, IVB and TTT have been approved for the
treatment of the SFF in all patients in advance.
Patients were followed up 1–2 month(s) after IVB or
TTT, and additional treatments were administered
depending on the persistence of SRF, as demonstrated
by OCT. For patients with progressively growing tumors
noted on fundus photography or B-scan ultrasonog-
raphy, which was suspected to be choroidal melanomas,
we recommended treatment with TTT, plaque brachy-
therapy, or enucleation.
Relationship between response of SFF to IVB, or to
observation and tumor growth, was analyzed using the
Fisher’s exact test. Statistical analyses were performed using
IBM SPSS Statistics, version 23 (IBM Corp., Armonk, NY,
USA).
Tumor volume and doubling time were calculated as
follows [21].
Tumor volume ¼ π
6
 tumor LBD2  height
Tumor doubling time = 0.301 × time from initial to
final volume / (log 10 final volume – log 10 initial
volume).
Results
A total of 19 eyes of 19 patients were enrolled in this
study. The mean age of patients was 45.05 ± 10.88 years
(range, 23–67 years). The mean LBD was 5.88 ± 1.46 mm
(range, 3.11–8.38 mm), and the mean height was 1.98 ±
0.57 mm (range, 0.45–2.86 mm). Ten patients (10/19;
52.6%) were women. The presence of orange pigment
Lee et al. BMC Ophthalmology          (2019) 19:103 Page 2 of 8
Ta
b
le
1
Pa
tie
nt
D
em
og
ra
ph
ic
s,
O
cu
la
r
Pa
ra
m
et
er
s,
Tu
m
or
G
ro
w
th
an
d
O
ut
co
m
es
of
In
tr
av
tir
ea
lB
ev
ac
iz
um
ab
In
je
ct
io
n
or
Tr
an
sp
up
ill
ar
y
Th
er
m
ot
he
ra
py
on
Su
bf
ov
ea
lF
lu
id
A
ss
oc
ia
te
d
w
ith
Sm
al
lP
ig
m
en
te
d
C
ho
ro
id
al
Le
si
on
s
Pa
tie
nt
N
o.
A
ge
ra
ng
e
/
Se
x
Pr
im
ar
y
th
er
ap
y
#N
o.
SF
F
re
so
lu
tio
n
A
dd
iti
on
al
th
er
ap
y
O
ra
ng
e
pi
gm
en
t
Fo
ve
al
di
st
an
ce
(m
m
)
D
is
c
di
st
an
ce
(m
m
)
In
iti
al
BC
VA
(S
ne
lle
n)
BC
VA
ch
an
ge
,
La
st
BC
VA
(S
ne
lle
n)
FU (m
o)
In
iti
al
LB
D
(m
m
)
In
iti
al
he
ig
ht
(m
m
)
Tu
m
or
gr
ow
th
,
La
st
LB
D
(m
m
)
*L
as
t
he
ig
ht
(m
m
)
1
50
–6
0/
F
IV
B
#3
N
on
e
Re
fu
se
d
Ye
s
5
3.
1
20
/4
0
W
or
se
,H
M
79
7.
4
2.
8
↑↑
↑,
9.
34
*1
0.
1
2
40
–5
0/
F
IV
B
#6
N
on
e
Br
ac
hy
Tx
.
Ye
s
0
2.
8
20
/5
0
W
or
se
,H
M
18
6.
12
1.
94
↑↑
↑,
8.
16
*5
.2
2
3
50
–6
0/
M
IV
B
#2
C
om
pl
et
e
En
uc
le
at
io
n
Ye
s
0
0
20
/2
00
W
or
se
,L
P-
48
5.
29
2.
06
↑↑
↑,
7.
76
*3
.8
7
4
30
–4
0/
M
IV
B
#2
N
on
e
Ye
s
0
2.
2
20
/5
0
St
ab
le
68
5.
59
1.
64
→
5
50
–6
0/
M
IV
B
#2
N
on
e
(S
po
nt
an
eo
us
re
so
lu
tio
n
af
te
r
30
m
o
O
bs
.)
Ye
s
1.
6
0
20
/4
0
Im
pr
ov
ed
,
20
/2
0
59
4.
4
2.
08
→
6
30
–4
0/
F
IV
B
#2
N
on
e
(S
po
nt
an
eo
us
re
so
lu
tio
n
af
te
r
15
m
o
O
bs
.)
Ye
s
0
2.
4
20
/2
5
W
or
se
,2
0/
63
19
3.
11
1.
28
→
7
30
–4
0/
M
IV
B
#1
C
om
pl
et
e
N
o
2.
1
5
20
/3
2
Im
pr
ov
ed
,
20
/2
0
74
8.
38
2.
86
→
8
60
–7
0/
F
IV
B
#4
Pa
rt
ia
l
N
o
0
1.
6
20
/6
3
St
ab
le
36
4.
1
0.
45
→
9
30
–4
0/
F
IV
B
#4
Pa
rt
ia
l
Ye
s
0
0
20
/2
5
W
or
se
,2
0/
40
39
5.
88
2.
38
→
10
40
–5
0/
F
IV
B
#3
N
on
e
TT
T
#2
Ye
s
0
1.
8
20
/4
0
W
or
se
,2
0/
63
72
6.
25
1.
92
↑, 6.
67
*2
.6
2
11
60
–7
0/
F
IV
B
#1
N
on
e
TT
T
#3
/
Br
ac
hy
Tx
.
Ye
s
0.
5
0
20
/6
3
W
or
se
,2
0/
12
5
51
6.
81
2.
23
↑, 7.
24
*2
.5
2
12
30
–4
0/
F
(1
)
IV
B
#1
(3
)
IV
B
#2
(5
)
IV
B
#2
N
on
e
(2
)T
TT
#2
(4
)T
TT
#1
/
Br
ac
hy
Tx
.
Ye
s
0
0
20
/1
00
W
or
se
,H
M
42
7.
11
1.
91
↑↑
↑,
10
.6
3*
4.
12
13
40
–5
0/
F
IV
B
#2
N
on
e
TT
T
#3
/
Br
ac
hy
Tx
.
N
o
1.
1
1.
1
20
/2
5
W
or
se
,2
0/
20
0
11
7.
74
2.
17
↑, 9.
08
*4
.0
9
14
30
–4
0/
M
IV
B
#3
Pa
rt
ia
l
TT
T
#2
N
o
0.
8
3.
6
20
/2
00
St
ab
le
54
6.
2
1.
1
→
15
20
–3
0/
M
TT
T
#4
C
om
pl
et
e
Ye
s
0
3
20
/6
3
Im
pr
ov
ed
,
20
/2
5
86
7.
17
2.
24
↓, 3.
96
*0
.7
16
50
–6
0/
M
TT
T
#2
C
om
pl
et
e
N
o
0.
75
0
20
/4
0
Im
pr
ov
ed
,
20
/2
0
30
4
1.
9
↓, 3.
94
*1
.3
8
17
40
–5
0/
F
TT
T
#1
Pa
rt
ia
l
N
o
0
0
20
/2
00
St
ab
le
22
7.
1
1.
96
→
18
30
–4
0/
M
TT
T
#1
C
om
pl
et
e
N
o
3.
5
2.
7
20
/6
3
Im
pr
ov
ed
,
20
/4
0
3
4.
72
2.
42
Ve
ry
sh
or
t
FU
19
50
–6
0/
M
O
bs
.
Sp
on
ta
ne
ou
s
re
so
lu
tio
n
Ye
s
0.
6
2.
9
20
/4
0
St
ab
le
36
4.
33
2.
24
→
IV
B
in
tr
av
itr
ea
lb
ev
ac
iz
um
ab
in
je
ct
io
n,
TT
T
tr
an
sp
up
ill
ar
y
th
er
m
ot
he
ra
py
,N
o.
nu
m
be
r,
SF
F
su
bf
ov
ea
lf
lu
id
,B
CV
A
be
st
co
rr
ec
te
d
vi
su
al
ac
ui
ty
,F
U
Fo
llo
w
-u
p
du
ra
tio
n,
m
o
m
on
th
s,
LB
D
la
rg
es
t
ba
se
di
am
et
er
,M
m
al
e,
F
fe
m
al
e,
O
bs
.O
bs
er
va
tio
n,
Tx
.T
he
ra
py
,H
M
ha
nd
m
ot
io
n,
LP
-
no
lig
ht
pe
rc
ep
tio
n
Lee et al. BMC Ophthalmology          (2019) 19:103 Page 3 of 8
was observed in 12 cases (63.1%). The mean distance to
the foveola was 0.84 ± 1.37 mm (range, 0–5 mm), and
the mean distance to the optic disc was 1.69 ± 1.55 mm
(range, 0–5 mm; Table 1). Demographics and tumor
features (including the presence of growth) of these 19
patients are summarized in Table 1.
Of the 19 patients who had symptomatic SFF with de-
creased visual acuity, 14 were treated with IVB and four
with TTT as the primary therapy, while one patient did not
undergo any treatment. Five of the 14 patients who re-
ceived IVB as the primary therapy were treated with TTT
as a secondary therapy. IVBs were administered on an aver-
age of 2.86 ± 1.46 times (range, 1–6). TTT was applied on
an average of 2.6 ± 0.55 sessions (range, 2–3) and 2.0 ± 1.41
sessions (range, 1–4) as the primary and secondary therap-
ies, respectively.
Outcome measures included resolution of SFF and
changes in visual acuity. Complete resolution of SFF was
achieved in two eyes (2/14; 14.3%) after IVB, and in
three eyes (3/4; 75%) after TTT. Partial resolution of
SFF occurred in three eyes (3/14; 21.4%) after IVB, and
in one eye (1/4; 25%) after TTT. All eyes showed a re-
sponse to TTT, whereas nine eyes (9/14; 64.3%) that re-
ceived IVB showed no improvement. Of these nine eyes,
spontaneous resolution of SFF occurred in two eyes, 30
and 15 months after the last IVB (patient 5 and 6). One
patient showed spontaneous resolution under observa-
tion without any treatment (patient 19; Tables 1 and 2).
Among 14 patients who received IVB as the primary
therapy, five underwent TTT as an additional treatment.
Following TTT, four out of these five patients (4/5; 80%)
demonstrated an additional advantage. Complete reso-
lution of SFF occurred in two eyes (2/5; 40%), and partial
resolution occurred in two eyes (2/5; 40%; Table 3).
Of the nine eyes that received IVB alone, visual acuity
improved in two eyes (2/9; 22%), remained stable in two
eyes (2/9; 22%), and worsened in five eyes (5/9; 56%). Of
the eyes that underwent TTT alone, visual acuity
improved in three eyes (3/4; 75%), and remained stable
in one eye (1/4; 25%)(Table 2).
Despite the small number of enrolled patients, TTT
showed better effects than IVB, in terms of fluid reduc-
tion and visual improvement. Figure 1 depicts the
findings of a patient who showed complete resolution of
SFF, improved visual acuity, and reduced tumor size
after TTT.
Among 15 eyes that received IVB or observation as
the primary therapy, tumor growth was detected in
seven eyes (7/15; 46.7%) (patients 1, 2, 3, 10, 11, 12,
and 13). Of the patients who underwent TTT alone,
none of them demonstrated tumor growth (0/4, 0%).
IVB was not effective in inhibiting tumor growth.
Of the patients who were followed up for at least 11
months, seven patients (7/18, 38.9%) showed tumor
growth during follow-up (mean, 46.9 months; range, 11–
86months). With the assumption of choroidal melan-
oma, we advised these seven patients with enlarged tu-
mors to undergo further treatment. Four patients
received ruthenium-106 brachytherapy (patients 2, 11,
12, and 13), one patient underwent TTT (patient 10),
and one patient underwent enucleation (patient 3). One
patient was advised to undergo brachytherapy, but he re-
fused and was lost to follow-up (patient 1).
In fact, one patient showed accelerated tumor growth
after IVBs (Fig. 2). This 58-year-old man had presented
with a 1-month history of decreased visual acuity. A
Table 2 Treatment Outcomes to Intravitreal Bevacizumab
Injection and Transpupillary Thermotherapy Regarding Response
of Subfoveal fluid and Visual Acuity
SFF; BCVA IVB TTT
Complete resolution;
Improved, No.(%)
2 (14.3%); 2 (22%) 3 (75%); 3 (75%)
Partial resolution;
Stable, No.(%)
3 (21.4%); 2 (22%) 1 (25%); 1 (25%)
No change; Worsen,
No.(%)
9 (64.3%); 5 (55.6%) 0 (0%); 0 (0%)
Total (No.) 14; 9 4; 4
SFF subfoveal fluid, BCVA best corrected visual acuity, IVB intravitreal
bevacizumab injection, TTT transpupillary thermotherapy, No. number
Table 3 Assessment of Treatment Response in the Patients Receiving Additional TTT after IVB as Primary Treatment for Subfoveal
Fluid
No. Age range /
Sex
1st Tx.
#No.
SFF 1st
Response
2nd Tx.
#No.
SFF 2nd
Response
Additional
therapy
Pre IVB SFF
height (μm)
Post IVB, pre TTT
SFF height (μm)
Post TTT SFF
height (μm)
Tumor
growth
10 40–50/F IVB#3 None TTT #2 Complete 114 167 0 ↑
11 70–80/F IVB#1 None TTT #3 Partial Brachy Tx. 380 390 54 ↑
13 40–50/F IVB#2 None TTT #3 Partial Brachy Tx. 292 671 315 ↑
14 40–50/M IVB#3 Partial TTT #2 Complete 265 116 0 →
12 40–50/F (1) IVB#1
(3) IVB#2
(5) IVB#2
None (2) TTT #2
(4) TTT #1
None Brachy Tx. ↑
IVB intravitreal bevacizumab injection, TTT transpupillary thermotherapy, No. number, Tx. Therapy, 1st primary, 2nd secondary, SFF subfoveal fluid, M male,
F female
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pigmented choroidal mass was noted at the fovea with a
height of 2.06mm and base diameter of 5.29mm, as mea-
sured by B-scan ultrasonography and fundus photography.
Calculated tumor volume was 30.18mm3. Shallow SFF
was observed on OCT. There was no change in tumor
size over the 4.5-month follow-up period without any
treatment. However, SFF persisted and IVBs were admin-
istered twice for treatment of the fluid. At 5months after
IVBs, prominent tumor growth was observed. Calculated
tumor volume was 66.29mm3, with a height of 2.96mm
and a base diameter of 6.54mm. Subsequently, the rate of
tumor growth showed further acceleration and eventually,
enucleation had to be performed.
In this study, treatment response (or lack of response)
to IVB may indicate choroidal melanoma or future pro-
gression to choroidal melanoma. Of the seven patients
who had SFF refractory to IVB, six showed tumor growth
during the follow-up period (6/7; 86%). When SFF showed
a decrease in response to IVB or observation, there was
no tumor growth in seven out of eight patients (7/8; 88%).
In conclusion, therapeutic response to IVB was valuable
in predicting subsequent tumor growth with statistical
significance (Fisher’s exact test, p = 0.010; Table 4).
Discussion
Bevacizumab, a recombinant humanized monoclonal
antibody that inhibits the vascular endothelial growth
factor (VEGF), was originally developed for the treat-
ment of metastatic colon cancer, and is still under inves-
tigation for numerous other primary and metastatic
cancers [2]. Moreover, bevacizumab has been shown to
be effective in reducing neurosensory detachment re-
lated with choroidal tumors [17–19]. With the expect-
ation of reducing tumor size and SFF, we administered
intravitreal bevacizumab injection (IVB) as a treatment
method for small pigmented choroidal lesions with
symptomatic subfoveal fluid (SFF).
In pigmented choroidal lesions with symptomatic leak-
age, various treatments, such as laser photocoagulation
[22–26], PDT with verteporfin [9–11, 25, 27–30], TTT
[8], and intravitreal anti-VEGF injections [5–7], have
been used; however, majority of them have been
reported in patients with CNV.
There have been several reports of intravitreal anti-
VEGF therapy for the treatment of SRF associated with
choroidal nevi, all of which were used to treat SRF with
co-existing CNV [5–7]. In these reports, intravitreal
anti-VEGF injection was reported as effective. In the
presence of CNV, it is easy to assume that SRF could be
reduced by anti-VEGF effect. However, in this study, by
excluding CNV-accompanying cases, we focused more
on the effect of the tumor itself on fluid, rather than the
CNV that is secondarily induced by the tumor. In our
study, IVB showed relatively less effectiveness in patients
with CNV-free small pigmented choroidal lesions. As
Fig. 1 Treatment results of transpupillary thermotherapy for subfoveal fluid associated with choroidal melanocytic lesions. A 23-year-old man
(Case 15) presented with 2-year history of decreased visual acuity of the left eye. His initial best corrected visual acuity (BCVA) was 20/63. a There
was a pigmented subretinal mass supero-temporal to the fovea, b with a height of 2.24 mm and base diameter of 7.17 mm, as measured by B-
scan ultrasonography. c Initial optical coherence tomography showed subretinal fluid at the macula. f After four sessions of transpupillary
thermotherapy, subretinal fluid completely resolved and BCVA improved to 20/25. d The tumor showed scarring changes, and (e) tumor size
decreased to 1.32 mm (height) by 4.13 mm (base diameter), as measured by B-scan ultrasonography. Improved vision and attached retinal status
were maintained for 46 months after the last treatment. Tumor size further decreased to 0.50 mm (height) by 4.18 mm (base diameter)
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IVB is primarily effective in neovascularization, the
difference in these results may be due to the presence of
CNV in pigmented choroidal lesions.
A previous study reported that subthreshold TTT was
effective in the treatment of SFF associated with small
pigmented choroidal lesions [8]. However, in that study,
subjects who had previous focal photocoagulation were
also included; moreover, the presence of CNV was not
confirmed. Out of 13 total patients enrolled, 11 (84.6%)
patients showed complete resolution of SRF, and nine
(69.3%) patients maintained or showed improvement in
the best corrected visual acuity. These results were similar
to ours. In our study, we found that TTT was not only
beneficial in patients without any previous therapy, but
also in those who had previously undergone IVB therapy.
In addition to the purpose of reducing SRF by IVB, we
also checked the effect of IVB in inhibiting tumor
growth. In the present study, the number of enrolled pa-
tients was small, and there was no control group. How-
ever, it was evident that IVB could not effectively inhibit
tumor growth. The non-beneficial effects of bevacizu-
mab on choroidal melanomas have been reported before.
Lima et al. showed a lack of benefit from bevacizumab
in the inhibition of tumor progression in their study of
three patients with choroidal melanoma who inadvert-
ently received multiple IVBs [31].
Fig. 2 Potential adverse effect of intravitreal bevacizumab injection on tumor growth. A 58-year-old man (Case 3) presented with 1-month history
of decreased visual acuity in the left eye. His initial best corrected visual acuity (BCVA) was 20/200. a There was a pigmented choroidal mass at
the fovea, with a height of 2.06 mm and a base diameter of 5.29 mm, as measured by B-scan ultrasonography. Shallow subfoveal fluid was
observed on optical coherence tomography. Calculated tumor volume was 30.18 mm3. Change in tumor size was monitored without any
treatment. b After 4.5 months, tumor growth was not observed. Calculated tumor volume was 28.98 mm3, with a height of 2.17 mm and a base
diameter of 5.05 mm. However, as subfoveal fluid persisted, intravitreal bevacizumab injections were administered twice at an interval of 1.5
months. c At 5 months after the last intravitreal injection, marked tumor growth was noted on B-scan ultrasonography and fundus photography.
Calculated tumor volume was 66.29 mm3, with a height of 2.96 mm and a base diameter of 6.54 mm. Tumor-doubling time from the period
before injections was 169.73 days. Subsequently, biopsy and treatment were recommended; however, the patient refused. d After 2 years, the
tumor had grown to a size of 280.10 mm3. Tumor-doubling time was calculated as 197.32 days. Finally, the patient underwent enucleation
Table 4 Relationship between Therapeutic Response of
Subfoveal fluid to Intravitreal Bevacizumab Injection or
Observation and Tumor Growth
Tumor growth Tumor size stable Total
SFF Decreased 1 7 (87.5%) 8
SFF Refractory 6 (85.7%) 1 7
Total 7 8 15
SFF subfoveal fluid
p = 0.010 (Fischer’s exact)
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In this paper, a case with no growth during observation
period and marked increase in growth after IVB were
reported. We were concerned, as such tumor growth
could be a possible adverse effect of bevacizumab. Re-
cently, similar cases of paradoxical enlargement were re-
ported in patients with uveal melanoma after IVB [32].
They used IVB as a neoadjuvant concept for treating uveal
melanoma, but observed that the tumor size increased ra-
ther than decreased, and the study was terminated early.
It was also possible that the observation of continued
growth was due to the natural history of uveal melanoma.
However, they suggested the need for caution when using
anti-VEGF agents for uveal melanomas.
In fact, since bevacizumab has been used to inhibit
primary or metastatic cancer in a different type of can-
cers, such finding from one case is not easily understood
intuitively. There have been conflicting reports on VEGF
levels in uveal melanoma [33–36]. A possible mechan-
ism for this paradoxical phenomenon is that alteration
of VEGF, one of the most potent tumor angiogenic
factors, by IVB may affect the dormancy, which is a dis-
tinctive feature of melanoma that differentiates it from
other cancers. Uveal melanoma is characterized by slow
progression and periods of dormancy (both primary and
metastatic tumors). It has been suggested that this dor-
mancy is associated with an avascular phase [37]. VEGF
expression of tumor tissue may be related to the dor-
mant status of uveal melanoma. Conversion to the an-
giogenic phenotype is due to an alteration in the balance
of inhibitory and stimulatory factors [37]. Based on this
possible mechanism of tumor growth related to IVB, it
may be assumed that anti-VEGF therapy and its with-
drawal influences the delicate balance among angiogenic
factors, thus eventually breaking the dormancy of uveal
melanoma. In addition, several previous experimental re-
ports can support the hypothesis that anti-VEGF therapy
may have a paradoxical effect, different from what is ori-
ginally expected. In one notable study in the field of can-
cer biology, it has been experimentally demonstrated
that the inhibition of angiogenesis pathway, such as
VEGF, could alter the natural history of a tumor by in-
creasing its invasion and metastasis [37, 38]. El Filali et
al. described an accelerated tumor growth following IVB
in murine B16 melanoma cell-containing eyes, and sug-
gested possible adverse effects of bevacizumab on chor-
oidal melanoma cells [36]. Of course, we observed the
adverse effect in only one case, which could have hap-
pened by chance, and we should not mistakenly make
any hasty generalization. However, IVB may have the
potential adverse effect, even at a low probability. Over-
all, IVB should be used with caution in treatment of
SRF associated with small pigmented choroidal lesion,
due to its lower therapeutic effect and possible adverse
effects.
In this study, treatment response (or lack of response)
to IVB may indicate choroidal melanoma or future pro-
gression to choroidal melanoma (Fisher’s exact test, p =
0.010). In other words, therapeutic response to IVB can
be used to diagnose or prognosticate malignancy. Small
pigmented choroidal lesions with SRF that do not re-
spond to IVB should be carefully observed.
Limitations of our study include a small sample size
and lack of a control group. Since randomization has
not been performed to IVB group and TTT group, com-
parison of the two treatment methods is not appropriate.
In addition, generalization of a case showing paradoxical
growth should be avoided.
Conclusion
In conclusion, IVB was not very effective in terms of
resolution of symptomatic SFF and improvement of
BCVA associated with small pigmented choroidal lesions
without CNV, and was unable to effectively inhibit
tumor growth. Treatment response (or lack of response)
to IVB may indicate choroidal melanoma or future pro-
gression to choroidal melanoma. Therefore, bevacizu-
mab should be used with caution in pigmented
choroidal lesions.
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